Medeon Biodesign (Taiwan) Performance
| 6499 Stock | TWD 40.00 0.40 1.01% |
The company secures a Beta (Market Risk) of 0.13, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Medeon Biodesign's returns are expected to increase less than the market. However, during the bear market, the loss of holding Medeon Biodesign is expected to be smaller as well. At this point, Medeon Biodesign has a negative expected return of -0.13%. Please make sure to verify Medeon Biodesign's coefficient of variation, jensen alpha, and the relationship between the mean deviation and standard deviation , to decide if Medeon Biodesign performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Medeon Biodesign has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest abnormal performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 1.1 B | |
| Total Cashflows From Investing Activities | -90.6 M | |
| Free Cash Flow | -302.4 M |
Medeon |
Medeon Biodesign Relative Risk vs. Return Landscape
If you would invest 4,380 in Medeon Biodesign on September 24, 2024 and sell it today you would lose (380.00) from holding Medeon Biodesign or give up 8.68% of portfolio value over 90 days. Medeon Biodesign is generating negative expected returns and assumes 1.6331% volatility on return distribution over the 90 days horizon. Simply put, 14% of stocks are less volatile than Medeon, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medeon Biodesign Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medeon Biodesign's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medeon Biodesign, and traders can use it to determine the average amount a Medeon Biodesign's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0787
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 6499 |
Estimated Market Risk
| 1.63 actual daily | 14 86% of assets are more volatile |
Expected Return
| -0.13 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Medeon Biodesign is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medeon Biodesign by adding Medeon Biodesign to a well-diversified portfolio.
Medeon Biodesign Fundamentals Growth
Medeon Stock prices reflect investors' perceptions of the future prospects and financial health of Medeon Biodesign, and Medeon Biodesign fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medeon Stock performance.
| Return On Equity | -0.1 | |||
| Return On Asset | -0.0639 | |||
| Profit Margin | (1.31) % | |||
| Operating Margin | (1.64) % | |||
| Current Valuation | 3.37 B | |||
| Shares Outstanding | 87.64 M | |||
| Price To Book | 1.29 X | |||
| Price To Sales | 19.67 X | |||
| Revenue | 68.96 M | |||
| EBITDA | (453.87 M) | |||
| Book Value Per Share | 43.26 X | |||
| Cash Flow From Operations | (293.38 M) | |||
| Earnings Per Share | 30.41 X | |||
| Total Asset | 4.36 B | |||
About Medeon Biodesign Performance
Evaluating Medeon Biodesign's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Medeon Biodesign has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Medeon Biodesign has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Medeon Biodesign performance evaluation
Checking the ongoing alerts about Medeon Biodesign for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medeon Biodesign help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medeon Biodesign generated a negative expected return over the last 90 days | |
| Medeon Biodesign has high likelihood to experience some financial distress in the next 2 years | |
| Medeon Biodesign generates negative cash flow from operations | |
| About 50.0% of the company shares are owned by insiders or employees |
- Analyzing Medeon Biodesign's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medeon Biodesign's stock is overvalued or undervalued compared to its peers.
- Examining Medeon Biodesign's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medeon Biodesign's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medeon Biodesign's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medeon Biodesign's stock. These opinions can provide insight into Medeon Biodesign's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Medeon Stock Analysis
When running Medeon Biodesign's price analysis, check to measure Medeon Biodesign's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medeon Biodesign is operating at the current time. Most of Medeon Biodesign's value examination focuses on studying past and present price action to predict the probability of Medeon Biodesign's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medeon Biodesign's price. Additionally, you may evaluate how the addition of Medeon Biodesign to your portfolios can decrease your overall portfolio volatility.